FFM
ACAD icon

Fairmount Funds Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Fairmount Funds Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-751,804
Closed -$12.3M – 17
2022
Q3 		$12.3M Hold
751,804
– – 2.16% 17
2022
Q2 		$10.6M Sell
751,804
-405,013
-35% -$7.56M 2.42% 18
2022
Q1 		$28M Buy
1,156,817
+740,000
+178% +$17.9M 6.62% 7
2021
Q4 		$9.73M Hold
416,817
– – 3.21% 11
2021
Q3 		$6.92M Sell
416,817
-7,000
-2% -$135K 2.52% 16
2021
Q2 		$10.3M Sell
423,817
-8,500
-2% -$192K 4.25% 10
2021
Q1 		$11.2M Sell
432,317
-18,000
-4% -$792K 4.7% 11
2020
Q4 		$24.1M Sell
450,317
-197,516
-30% -$9.81M 8.61% 4
2020
Q3 		$26.7M Buy
647,833
+62,316
+11% +$2.69M 11.32% 2
2020
Q2 		$28.4M Sell
585,517
-18,000
-3% -$864K 12.66% 1
2020
Q1 		$25.5M Buy
603,517
+87,729
+17% +$3.61M 15.47% 1
2019
Q4 		$22.1M Buy
+515,788
New +$22.4M 13.37% 3

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fairmount Funds Management's ACAD Position: Q4 2022 in Review

Fairmount Funds Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2022, closing a stake of 751,804 shares — an estimated $12.3M sold.

Fairmount Funds Management first reported a position in ACAD in Q4 2019 and held it in 12 quarters. The position peaked at $28.4M in Q2 2020. 227 funds tracked by Wall St. Rank hold ACAD as of Q4 2022.

  • Fairmount Funds Management reported no remaining Acadia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Fairmount Funds Management sold 751,804 Acadia Pharmaceuticals shares in Q4 2022, an estimated $12.3M.
  • Fairmount Funds Management first reported a position in Acadia Pharmaceuticals in Q4 2019 and held it in 12 quarters.
  • Fairmount Funds Management's Acadia Pharmaceuticals position peaked at $28.4M in Q2 2020.
  • 227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2022.

Based on Fairmount Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.